Zydus Lifesciences Analyst Rating
based on 32 analysts
48.39%
Buy
32.26%
Hold
19.35%
Sell
Based on 32 analysts offering long term price targets for Zydus Lifesciences. An average target of ₹1079.53
Source: S&P Global Market Intelligence
Zydus Lifesciences Share analysis
Zydus Lifesciences price forecast by 32 analysts
Upside of8.53%
High
₹1380
Target
₹1079.53
Low
₹794
Zydus Lifesciences target price ₹1079.53, a slight upside of 8.53% compared to current price of ₹994.65. According to 32 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Zydus Lifesciences revenue growth forecast
Expected growth rate Q1, FY2027:29.43%
Forecast
Actual
Including amortisation and stock based compensations
Zydus Lifesciences EPS growth forecast
EPS estimate Q1, FY2027:14.21%
Forecast
Actual
Source: S&P Global Market Intelligence
Zydus Lifesciences Performance
Day's Low
Day's High
₹980.95Day's Price Range₹1,000.952 Week's Low
52 Week's High
₹68652-Week Price Range₹1,324.3
| Returns % | |
| 1 Month Return | + 1.54 % |
| 3 Month Return | -2.72 % |
| 1 Year Return | + 40.31 % |
| Market Stats | |
| Previous Close | ₹988.15 |
| Open | ₹992.00 |
| Volume | 8.80L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹99,431.01Cr |
Zydus Lifesciences Key Statistics
| P/E Ratio | 23.32 |
| PEG Ratio | 1.56 |
| Market Cap | ₹99,431.01 Cr |
| P/B Ratio | 6.43 |
| EPS | 38.31 |
| Dividend Yield | 0.3 |
| Sector | Pharmaceuticals |
| ROE | 23.45 |
Zydus Lifesciences Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹99,431.01 Cr | 54.52% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹12,534.65 Cr | -3.67% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| BUY | ₹67,752.08 Cr | 28.8% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| BUY | ₹58,008.46 Cr | 24.18% | 0.53 | NA | NA | |
| BUY | ₹34,779.91 Cr | 5.31% | 0.56 | ₹589 Cr | ₹3,453 Cr |
About Zydus Lifesciences
The company has a strong presence in the global market and is known for its high-quality pharmaceutical products. It manufactures a wide range of generic and specialty drugs, including cardiovascular, anti-infective, anti-diabetic, and oncology medicines. Zydus also produces over-the-counter products and nutritional supplements. Some of its top products include Zetia, Atorvastatin, and Metformin.
Zydus Lifesciences Ltd is also known for its popular brands, such as Cadila, Nutralite, and Zydus Wellness. The company has a strong presence in the Indian market, with its products being sold in more than 20,000 stores across the country. It also exports its products to over 100 countries worldwide.
Share Price: ₹994.65 per share as on 17 Jan, 2025 04:01 PM
Market Capitalisation: ₹99,431.01Cr as of today
Revenue: ₹5,113.60Cr as on September 2024 (Q3 24)
Net Profit: ₹898.10Cr as on September 2024 (Q3 24)
Listing date: 18 Apr, 2000
Chairperson Name: Pankaj R Patel
| Organisation | Zydus Lifesciences |
| Headquarters | Ahmedabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Zydus Lifesciences Ltd
Zydus Lifesciences Receives Positive Upgrades and Breakout - 09 Jan, 2025
Zydus Lifesciences received a 'Buy' upgrade from Nomura with a target of Rs 1,140, driven by Sitagliptin growth. The stock shows a positive breakout, with support at Rs 1,003 and potential upside to Rs 1,130. Additionally, FDA priority review for CUTX-101 enhances its market position in the US diabetes sector.Zydus Lifesciences Receives FDA Acceptance for Drug - 08 Jan, 2025
Zydus Lifesciences has received FDA acceptance for its new drug application for CUTX-101, indicating progress in its specialty portfolio and a strong generic pipeline.Zydus Lifesciences Gains from CVS Caremark Agreement - 07 Jan, 2025
Zydus Lifesciences announced a partnership with CVS Caremark to include its diabetes medications in the formulary, boosting stock by 5.2%. The FDA also granted priority review for CUTX-101, a potential treatment for Menkes disease.Zydus Lifesciences Extends Business Transfer Deadline - 27 Dec, 2024
Zydus Lifesciences and Sterling Biotech have mutually agreed to extend the completion date for the business transfer of Sterling's API business to March 31, 2025, due to pending conditions.Zydus Secures USFDA Approval for Anesthetic Cream - 19 Dec, 2024
Zydus Lifesciences has received USFDA approval for Lidocaine and Prilocaine Cream, a topical anesthetic, with annual sales of $22.05 million in the US market. This marks the company's 412th approval, reflecting its strong presence in the US generic drug market.
Insights on Zydus Lifesciences Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 5.59% to 7.52% in Sep 2024 quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, ZYDUSLIFE has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 6.80% to 6.85% in Sep 2024 quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 46.6% return, outperforming this stock by 10.6%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 74.98% of holdings in Sep 2024 quarter
NEGATIVE IMPACTPrice Dip
In the last 7 days, ZYDUSLIFE stock has moved down by -2.6%
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 1.41K Cr → 911.2 Cr (in ₹), with an average decrease of 35.8% per quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 6.27K Cr → 5.30K Cr (in ₹), with an average decrease of 15.4% per quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 7.24% to 6.57% in Sep 2024 quarter
Zydus Lifesciences Financials
Index Inclusions
Zydus Lifesciences Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 74.98% | 0.00 | |
| Foreign Institutions | 7.52% | 34.61 | |
| Mutual Funds | 6.57% | ||
| Retail Investors | 6.85% | 0.71 | |
| Others | 4.08% |
Zydus Lifesciences Key Indicators
Zydus Lifesciences Valuation
Zydus Lifesciences in the last 5 years
Lowest (7.34x)
March 7, 2022
Today (23.32x)
January 17, 2025
Industry (54.95x)
January 17, 2025
Highest (34.62x)
March 26, 2024
Zydus Lifesciences Earnings and Dividends
Zydus Lifesciences Ltd Earnings Results
Zydus Lifesciences Ltd’s net profit jumped 13.8% since last year same period to ₹911.20Cr in the Q2 2024-2025. On a quarterly growth basis, Zydus Lifesciences Ltd has generated -35.83% fall in its net profits since last 3-months.
Read More about Earnings ResultsZydus Lifesciences Ltd Dividends May,2024
In the quarter ending March 2024, Zydus Lifesciences Ltd has declared dividend of ₹3 - translating a dividend yield of 0.90%.
Read More about Dividends
Zydus Lifesciences Technicals Summary
Bearish
Neutral
Bullish
Zydus Lifesciences Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Zydus Lifesciences Ltd
Zydus Lifesciences Ltd share price today stands at ₹994.65, Open. ₹992 ; Previous Close. ₹988.15 ; High. ₹1000.9 ; Low. ₹980.95 ; 52 Week High. ₹1324.3 ; 52 Week Low: ₹686.
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Zydus Lifesciences Ltd shares.
Zydus Lifesciences Ltd is listed on NSE
Zydus Lifesciences Ltd is listed on BSE
- Today’s highest price of Zydus Lifesciences Ltd is ₹1000.9.
- Today’s lowest price of Zydus Lifesciences Ltd is ₹980.95.
PE Ratio of Zydus Lifesciences Ltd is 23.32
PE ratio = Zydus Lifesciences Ltd Market price per share / Zydus Lifesciences Ltd Earnings per share
Today’s traded volume of Zydus Lifesciences Ltd(ZYDUSLIFE) is 8.80L.
Today’s market capitalisation of Zydus Lifesciences Ltd(ZYDUSLIFE) is ₹99431.01Cr.
| Zydus Lifesciences Ltd(ZYDUSLIFE | Price |
|---|---|
52 Week High | ₹1324.3 |
52 Week Low | ₹686 |
Zydus Lifesciences Ltd(ZYDUSLIFE) share price is ₹994.65. It is down -24.89% from its 52 Week High price of ₹1324.3
Zydus Lifesciences Ltd(ZYDUSLIFE) share price is ₹994.65. It is up 44.99% from its 52 Week Low price of ₹686
| Zydus Lifesciences Ltd(ZYDUSLIFE | Returns |
|---|---|
1 Day Returns | 6.5% |
1 Month Returns | 1.54% |
3 Month Returns | -2.72% |
1 Year Returns | 40.31% |